ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2324

Predictors of Refracture in Patients with Hip Fragility Fracture

Sara Ganhão1,2, Miguel Guerra3, Francisca Aguiar1,2, Georgina Terroso1, Romana Vieira3, Diana Gonçalves4, Teresa Martins-Rocha2,5, Raquel Ferreira1,2, Ana Águeda2,6, Tiago Meirinhos7, Eva Mariz1,2, Raquel Lucas8, Miguel Bernardes1,2, Carlos Vaz1,2 and Lúcia Costa1, 1Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, 2Faculty of Medicine, Oporto University, Oporto, Portugal, 3Rheumatology, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal, 4Rheumatology, Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal, 5Rheumatology Department, Centro Hospitalar de São João, Porto, Portugal, Oporto, Portugal, 6Rheumatology, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, 7Serviço de Reumatologia, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, Aveiro, Portugal, 8Public Health, Centro Hospitalar de São João, Oporto, Portugal

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Elderly, fractures and osteoporosis, Hip

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Title: Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Hip fractures are associated with substantially elevated morbidity and mortality and thus represent a serious public health problem. The purpose of this study is to assess cumulative refracture free survival probability and possible predictors of refracture in patients older than 65 years admitted by hip fragility fracture.

Methods: Longitudinal retrospective study of patients referred to the Rheumatology department’s Fracture Liaison Service (FLS) from march 2015 until march 2017. Demographic and clinical data were collected. Statistical analysis was performed with STATA. Survival cumulative probabilities were calculated with Kaplan-Meyer curves. Hazard ratios (HR) were calculated through cox regression, adjusted to age and degree of dependence.

Results: 522 patients were referred to the FLS, with a median age (min-max) of 84 years (65-103); 79,7% (N=416) were female. 47 out of 522 had a subsequent fragility fracture (9%). The cumulative survival probability without refracture at 1, 6, 12 and 24 months was 99,4%, (95%CI [98,2-99,8]), 96% (95%CI [93,8-97,4]), 93% (95%CI [90,2-95,0]) and 89,3% (95%CI [85,8-92,0], respectively. Neurologic disease and chronic obstructive pulmonary disease (COPD) were both predictors of worst refracture free survival outcome (HR 2,37, 95%CI [1,05-5,37] and HR 3,25, 95%CI [1,09-9,61], respectively). Gender, age, body mass index, degree of dependence, fracture and intervention type, calcium intake, sedative drugs, radiographic vertebral fractures, total femur BMD and T-score, vitamin D, osteocalcin and βcrosslaps, discharge to home or institution, supplementation with calcium and vitamin D and anti-osteoporotic treatment didn’t have significant impact on survival cumulative probabilities of refracture.

Figure 1: Cumulative refracture free survival probability

Figure 2: Cumulative refracture free survival probability

 (with neurologic diseases Vs without neurologic diseases)

Figure 3: Cumulative refracture free survival probability

 (with COPD Vs without COPD)

Conclusion: Knowledge of the predictors of refracture is essential for secondary prevention. Our sample suggests that neurologic disease and COPD may increase the risk of subsequent fracture after prior fragility fracture, but further studies are needed.


Disclosure: S. Ganhão, None; M. Guerra, None; F. Aguiar, None; G. Terroso, None; R. Vieira, None; D. Gonçalves, None; T. Martins-Rocha, None; R. Ferreira, None; A. Águeda, None; T. Meirinhos, None; E. Mariz, None; R. Lucas, None; M. Bernardes, Pfizer, Inc., 9,Lilly, 9,Janssen, 9,Merck & Co., 9,GlaxoSmithKline, 9; C. Vaz, None; L. Costa, None.

To cite this abstract in AMA style:

Ganhão S, Guerra M, Aguiar F, Terroso G, Vieira R, Gonçalves D, Martins-Rocha T, Ferreira R, Águeda A, Meirinhos T, Mariz E, Lucas R, Bernardes M, Vaz C, Costa L. Predictors of Refracture in Patients with Hip Fragility Fracture [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/predictors-of-refracture-in-patients-with-hip-fragility-fracture/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-refracture-in-patients-with-hip-fragility-fracture/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology